According to the European Hereditary Tumour Group (EHTG) and the European Society of Coloproctology (ESCP) guidelines, the prevalence of pathogenic MMR gene carriers is estimated to be approximately one in 300, which equates to around 2.5 million people in Europe [19]. The gene discussed is MRC1; the disease is neoplasm.